| Ident. | Authors (with country if any) | Title |
|---|
| 000351 |
Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark] | The Risk of Valvular Regurgitation in Patients with Parkinson's Disease Treated with Dopamine Receptor Agonists |
| 000644 |
Morvarid Karimi [États-Unis] ; Stephen M. Moerlein [États-Unis] ; Tom O. Videen [États-Unis] ; Robert R. Luedtke [États-Unis] ; Michelle Taylor [États-Unis] ; Robert H. Mach [États-Unis] ; Joel S. Perlmutter [États-Unis] | Decreased Striatal Dopamine Receptor Binding in Primary Focal Dystonia: A D2 or D3 Defect? |
| 000D27 |
Susanne A. Schneider [Royaume-Uni] ; Vrajesh Udani [Inde] ; Charulata Sawant Sankhla [Inde] ; Kailash P. Bhatia [Royaume-Uni] | Recurrent Acute Dystonic Reaction and Oculogyric Crisis Despite Withdrawal of Dopamine Receptor Blocking Drugs |
| 000F07 |
Elena Garcia-Martin [Espagne] ; Carmen Martinez [Espagne] ; Hortensia Alonso-Navarro [Espagne] ; Julián Benito-Leon [Espagne] ; Inmaculada Puertas [Espagne] ; Lluisa Rubio [Espagne] ; Tomás Lopez-Alburquerque [Espagne] ; José A. G. Agundez [Espagne] ; Félix Javier Jimenez-Jimenez [Espagne] | Dopamine Receptor D3 (DRD3) Genotype and Allelic Variants and Risk for Essential Tremor |
| 000F77 |
Jee-Young Lee [Corée du Sud] ; EUN KYUNG LEE [Corée du Sud] ; SUNG SUP PARK [Corée du Sud] ; Ji-Yeon Lim [Corée du Sud] ; HEE JIN KIM [Corée du Sud] ; JI SUN KIM [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Association of DRD3 and GRIN2B with Impulse Control and Related Behaviors in Parkinson's Disease |
| 001C13 |
Kristian Winge [Danemark] ; Clare J. Fowler [Royaume-Uni] | Bladder dysfunction in parkinsonism : Mechanisms, prevalence, symptoms, and management |
| 002039 |
Jaume Campdelacreu [Espagne] ; Hatice Kumru [Espagne] ; Eduard Tolosa [Espagne] ; Josep Valls-Sole [Espagne] ; Antoni Benabarre [Espagne] | Progressive supranuclear palsy syndrome induced by clebopride |
| 002171 |
Ida Rissling [Allemagne] ; Frank Geller [Allemagne] ; Oliver Bandmann [Allemagne] ; Karim Stiasny-Kolster [Allemagne] ; Yvonne Körner [Allemagne] ; Charlotte Meindorfner [Allemagne] ; Hans-Peter Krüger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; J. Carsten Möller [Allemagne] | Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks" |
| 002316 |
Sebastian Paus [Allemagne] ; Hans Michael Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Gert Seeger [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease |
| 002467 |
Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study |
| 002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 002666 |
Giulio Cicarelli [Italie] ; Maria Teresa Pellecchia [Italie] ; Giuseppe De Michele [Italie] ; Gilberto Pizzolato [Italie] ; Paolo Barone [Italie] | Paradoxical response to apomorphine in a case of atypical parkinsonism |
| 002672 |
William G. Ondo [États-Unis] ; Joel K. Levy [États-Unis] ; Kevin Dat Vuong [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis] | Olanzapine treatment for dopaminergic-induced hallucinations |
| 002708 |
Petr Kanovsky [République tchèque] ; Dagmar Kubova [République tchèque] ; Martin Bares [République tchèque] ; Hana Hortova [République tchèque] ; Hana Streitova [République tchèque] ; Ivan Rektor [République tchèque] ; Vladimir Znojil [République tchèque] | Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: Results of a two-year, prospective follow-up |
| 002777 |
Guillermo Paradiso [Canada] ; Farooq Khan [Canada] ; Robert Chen [Canada] | Effects of apomorphine on flexor reflex and periodic limb movement |
| 002789 |
| Drugs to treat dementia and psychosis |
| 002811 |
| DA agonists: Non-Ergot derivatives: Piribedil |
| 002812 |
| DA agonists: Non-Ergot derivatives: Apomorphine |
| 002813 |
| DA agonists: Ergot derivatives: Pergolide |
| 002814 |
| DA agonists: Ergot derivatives: Lisuride |
| 002815 |
| DA agonists: Ergot derivatives: Dihydroergocryptine (DHEC) |
| 002816 |
| DA agonists: Ergot derivatives: Cabergoline |
| 002863 |
| Amantadine and other antiglutamate agents |
| 002881 |
Han-Cheng Wang [Taïwan] ; YOLOUNG HSIEH [Taïwan] | Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy |
| 002897 |
F. Tracik [Allemagne] ; G. Ebersbach [Allemagne] | Sudden daytime Sleep onset in Parkinson's disease: Polysomnographic recordings |
| 002919 |
William Koller [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Mariese Hely [Australie] | Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations |
| 002927 |
Anette Schrag [Royaume-Uni] ; Michael Trimble [Royaume-Uni] | Poetic talent unmasked by treatment of Parkinson's disease |
| 002952 |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002966 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Alfredo Berardelli [Italie] ; Francesca De Pandis [Italie] ; Stefano Ruggieri [Italie] | Long-duration effect and the postsynaptic compartment : Study using a dopamine agonist with a short half-life |
| 002A28 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 002A78 |
C. W. Olanow [États-Unis] ; A. H. V. Schapira [Royaume-Uni] ; T. Roth [États-Unis] | Waking up to sleep episodes in Parkinson's disease |
| 002A95 |
L. M. Shulman [États-Unis] ; A. Minagar [États-Unis] ; A. Rabinstein [États-Unis] ; W. J. Weiner [États-Unis] | The use of dopamine agonists in very elderly patients with Parkinson's disease |
| 002B22 |
N. A. Leopold [États-Unis] | Risperidone treatment of drug-related psychosis in patients with Parkinsonism |
| 002B23 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 002C46 |
A. Rapaport [Israël] ; M. Sadeh [Israël] ; D. Stein [Israël] ; J. Levine [Israël] ; P. Sirota [Israël] ; T. Mosheva [Israël] ; S. Stir [Israël] ; A. Elitzur [Israël] ; I. Reznik [Israël] ; D. Geva [Israël] ; J. M. Rabev [Israël] | Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia |
| 002C54 |
J. H. Friedman [États-Unis] ; S. A. Factor | Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease |
| 002C57 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine : An underutilized therapy for Parkinson's disease |
| 002C97 |
J. L. Montastruc [France] ; Olivier Rascol [France] ; J.-M. Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
| 002D07 |
J. E. Ahlskog [États-Unis] ; R. J. Uitti [États-Unis] ; M. K. O'Connor [États-Unis] ; D. M. Maraganore [États-Unis] ; J. Y. Matsumoto [États-Unis] ; K. F. Stark [États-Unis] ; M. F. Turk [États-Unis] ; O. L. Burnett [États-Unis] | The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease |
| 002D32 |
A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges |
| 002D46 |
C. Trenkwalder [Allemagne] ; A. S. Walters [États-Unis] ; W. A. Hening [États-Unis] ; S. Chokroverty [États-Unis] ; A. Antonini [États-Unis] ; V. Dhawan [États-Unis] ; D. Eidelberg [États-Unis] | Positron emission tomographic studies in restless legs syndrome |
| 002E01 |
P. Barbanti [Italie] ; G. Fabbrini [Italie] ; A. Ricci [Italie] ; R. Cerbo [Italie] ; E. Bronzetti [Italie] ; B. Caronti [Italie] ; C. Calderaro [Italie] ; L. Felici [Italie] ; F. Stocchi [Italie] ; G. Meco [Italie] ; F. Amenta [Italie] ; G. L. Lenzi [Italie] | Increased expression of dopamine receptors on lymphocytes in Parkinson's disease |
| 002E11 |
M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine] | GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine |
| 002E65 |
E. Grünblatt [Israël] ; S. Mandel [Israël] ; T. Berkuzki [Israël] ; M. B. H. Youdim [Israël] | Apomorphine protects against MPTP-induced neurotoxicity in mice |
| 002E66 |
M. Merello [Argentine] ; J. Balej [Argentine] ; M. Delfino [Argentine] ; A. Cammarota [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease |
| 002E67 |
E. Moro [Italie] ; A. Albanese [Italie, Suisse] | Apomorphine and levodopa challenge in patients with a focal midbrain lesion |
| 002E78 |
J.-L. Montastruc [France] ; M. Ziegler [France] ; Olivier Rascol [France] ; M. Malbezin [France] | A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 002E80 |
W. Ondo [États-Unis] ; C. Hunter [États-Unis] ; M. Almaguer [États-Unis] ; Joseph Jankovic [États-Unis] | A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease |
| 002F03 |
J. Winkelmann [Allemagne] ; T. C. Wetter [Allemagne] ; K. Stiasny [Allemagne] ; W. H. Oertel [Allemagne] ; C. Trenkwalder [Allemagne] | Treatment of restless leg syndrome with pergolide : An open clinical trial |
| 002F10 |
T. Van Laar [Pays-Bas] ; B. Van Hilten [Pays-Bas] ; C. Neef [Pays-Bas] ; A. W. F. Rutgers [Pays-Bas] ; S. Pavel [Pays-Bas] ; J. A. Bruijn [Pays-Bas] | The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease : A histologic study |
| 002F97 |
M. Naumann [Allemagne] ; W. Pirker [Autriche] ; K. Reiners [Allemagne] ; K. W. Lange [Allemagne] ; G. Becker [Allemagne] ; T. Brücke [Allemagne] | Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia : A SPECT study using [123I] epidepride and [123I] β-CIT |
| 003053 |
M. Merello [Argentine] ; A. Cammarota [Argentine] ; M. I. Nouzeilles [Argentine] ; O. Betti [Argentine] ; R. Leiguarda [Argentine] | Confirmation of the antidyskinetic effect of posteroventral pallidotomy by means of an intraoperative apomorphine test |
| 003079 |
J. D. O'Sullivan [Australie] ; A. J. Hughes [Australie] | Apomorphine-induced penile erections in Parkinson's disease |
| 003081 |
M. Gassen [Israël] ; A. Gross [Israël] ; M. B. H. Youdim [Israël] | Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine |
| 003097 |
R. B. Jr Dewey [États-Unis] ; D. M. Maraganore [États-Unis] ; J. E. Ahlskog [États-Unis] ; J. Y. Matsumoto [États-Unis] | A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease |
| 003160 |
K. A. Gwinn [États-Unis] ; J. N. Caviness [États-Unis] | Risperidone-induced tardive dyskinesia and parkinsonism |
| 003237 |
J. F. Lipinski [États-Unis] ; F. R. Sallee [États-Unis] ; C. Jackson [États-Unis] ; G. Sethuraman [États-Unis] | Dopamine agonist treatment of Tourette disorder in children : Results of an open-label trial of pergolide |
| 003311 |
F. Stocchi [Italie] ; M. F. De Pandis [Italie] ; F. A. Delfino [Italie] ; T. Anselmo [Italie] ; D. Frongillo [Italie] | Transient atrial fibrillation after subcutaneous apomorphine bolus |
| 003359 |
M. Jauss [Allemagne] ; P. Krack [Allemagne] ; M. Franz [Allemagne] ; R. Klett [Allemagne] ; R. Bauer [Allemagne] ; B. Gallhofer [Allemagne] ; W. Dorndorf [Allemagne] | Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome |
| 003376 |
F. Tison [France] ; L. Wiart [France] ; M. Guatterie [France] ; N. Fouillet [France] ; V. Lozano [France] ; P. Henry [France] ; M. Barat [France] | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease |
| 003386 |
T. E. Eichhorn [Allemagne] ; T. Gasser [Allemagne] ; N. Mai [Allemagne] ; C. Marquardt ; G. Arnold [Allemagne] ; J. Schwarz [Allemagne] ; W. H. Oertel [Allemagne] | Computational analysis of open loop handwriting movements in Parkinson's disease : A rapid method to detect dopamimetic effects |
| 003412 |
A. P. Sempere [Espagne] ; J. Duarte [Espagne] ; F. Garcia [Espagne] ; C. Cabezas [Espagne] ; F. Coria [Espagne] ; L. E. Claveria [Espagne] | An estimate of the risk of movement disorders associated with the chronic use of clebopride |
| 003413 |
L. Smith [Royaume-Uni] ; M. De Salvia [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets |
| 003421 |
T. Van Laar [Pays-Bas] ; C. Neef [Pays-Bas] ; M. Danhof [Pays-Bas] ; K. I. Roon [Pays-Bas] ; R. A. C. Roos [Pays-Bas] | A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease |
| 003463 |
S. Przedborski [Belgique] ; M. Levivier ; C. Raftopoulos ; A. B. Naini ; J. Hildebrand [Belgique] | Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans |
| 003527 |
S. T. Gancher [États-Unis] ; J. G. Nutt [États-Unis] ; W. R. Woodward | Apomorphine infusional therapy in Parkinson's disease : clinical utility and lack of tolerance |
| 003736 |
P. G. Strange [Royaume-Uni] | Dopamine receptors in the basal ganglia: relevance to Parkinson's disease |
| 003920 |
J. M. Cedarbaum ; M. Clark ; L. H. Toy ; A. Green-Parsons | Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease : evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation |
| 003955 |
J. Vaamonde ; M. R. Luquin ; J. A. Obeso | Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease |
| 003A74 |
W. Koller ; G. Herbster ; J. Gordon | PHNO, a novel dopamine agonist, in animal models of parkinsonism |
